Cohort of hepatitis B research in Amsterdam.
Recruiting
- Conditions
- cirrhosis, hepatitis B virus, hepatocellular carcinoma, viral load
- Registration Number
- NL-OMON21330
- Lead Sponsor
- niversity Medical Center UtrechtPublic Health Service (GGD) Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 172
Inclusion Criteria
1. HBsAg-positivity;
2. Serum sample available from the screening programme at the Public Health Service;
Exclusion Criteria
1. Subjects coinfected with human immunodeficiency virus (HIV), hepatitis D virus (HDV) or
hepatitis C virus (HCV);
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main study parameters are any of following complications:<br /><br>1. Liver cirrhosis;<br /><br>2. Death related to HBV morbidity.
- Secondary Outcome Measures
Name Time Method Secondary study parameters are:<br /><br>1. HCC;<br /><br>2. Liver transplantation;<br /><br>3. End-stage liver disease (Child-Pugh B or C);<br /><br>4. Viral load of hepatitis B (comparison of historic and follow-up serum samples);<br /><br>5. Parameters of activation, exhaustion and apoptosis in various subsets of immunological cells.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways link HBV viral load to cirrhosis progression in the NL-OMON21330 Amsterdam cohort?
How does non-invasive HBsAg quantification correlate with HCC risk in the NL-OMON21330 HBV cohort study?
Which biomarkers predict treatment response in HBV-infected cirrhosis patients within the NL-OMON21330 observational trial?
What adverse events are associated with HBV-related cirrhosis in the NL-OMON21330 Amsterdam cohort study?
How does the NL-OMON21330 cohort compare to other HBV studies in identifying early HCC biomarkers using non-invasive methods?